Biotech entity
Of the tracked stories, 1 of 2 also mention COVID-19 Vaccine, the most common co-covered peer. The 49-day window averages about 0.3 stories each week. Each story carries 2 original sources on average, compared with 2.3 for the broader beat in this window.
Last mentioned: 4d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 1 of 2 also mention COVID-19 Vaccine, the most common co-covered peer. The 49-day window averages about 0.3 stories each week. Each story carries 2 original sources on average, compared with 2.3 for the broader beat in this window. The 5.5 average consequence score is below the beat benchmark of 5.8 in the same window. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. This profile follows 2 Biotech stories mentioning Jim Cramer across the period from July 21, 2026 to September 7, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 218 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Jim Cramer. Shared-story counts are live from our verified record — not editorial picks.
Coverage Highlights Market Divergence
Financial media report on the stock's surge and note some Wall Street price targets are more upbeat than Cramer's caution.
Cramer Calls NUVB 'Pure Speculation'
On CNBC's Mad Money, Jim Cramer warns Nuvation Bio trades on what pipeline drugs might do someday rather than steady revenue.
FDA Grants Fast Track Designation to Safusidenib
Nuvation Bio's experimental brain cancer drug safusidenib receives FDA Fast Track status for IDH1-mutant glioma.
Cramer Endorsement & 109% YTD Gain
Motley Fool highlights 109% year-to-date surge and Jim Cramer's comment that Moderna is 'finally investable again'.
Quarterly Update
Moderna reports a 26% reduction in operating expenses, reiterates up to 10% revenue growth target for 2026.
Post-Pandemic Decline
Demand for COVID vaccines wanes, RSV sales miss expectations, and CMV candidate fails; stock loses over 80% from peak.
COVID Vaccine Success
Moderna's COVID-19 vaccine drives record revenue; stock surges over 2,000% from early 2020 through August 2021.
Nuvation Bio's experimental brain cancer drug safusidenib won FDA Fast Track in August 2026, but Jim Cramer on CNBC called the surging stock pure speculation. While IBTROZI showed commercial traction as the most-prescribed new lung cancer treatment in early 2026, most value still hinges on late-stage pipeline data.
Source: aol.com · finance.yahoo.com
Moderna’s cost cuts and pipeline milestones, from RSV commercialization to latent virus programs, are restoring biotech investor confidence despite past setbacks.
Source: Adria Cimino (us) · fool.com
Jim Cramer is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
